echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Radiol: Use MRI to evaluate the chemotherapy effect of bone tumors and evaluate survival

    Eur Radiol: Use MRI to evaluate the chemotherapy effect of bone tumors and evaluate survival

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Osteosarcoma (OS) is the most common primary malignant bone tumor, with the highest incidence in children and adolescents.


    Osteosarcoma (OS) is the most common primary malignant bone tumor with the highest incidence in children and adolescents.


    In osteosarcoma, chemotherapy-induced tumor necrosis is a recognized prognostic predictor.


    Magnetic resonance imaging (MRI) has become an important method for the diagnosis of primary bone tumors and the detection of postoperative tumor recurrence.


    Recently, a study published in the journal European Radiology evaluated the parameters of diffusion-weighted imaging (DWI) and dynamic enhanced magnetic resonance imaging (DCE-MRI) of the tumor and the surrounding area of ​​OS patients, which are the tumor histology of neoadjuvant chemotherapy before surgery.


     

    Methods of evaluating patients with osteosarcoma: This study included 34 patients with OS.


    Methods of evaluating patients with osteosarcoma: This study included 34 patients with OS.


    In the tumor area, there is moderate evidence that responders have lower post-Ktrans than poor responders (p = 0.


    Figure 1 A ROC curve of tumor and peritumoral area parameters.


    Figure 1 A ROC curve of tumor and peritumoral area parameters.


     

    Figure 2 Event-free survival curves of subgroups stratified according to the median value of (a) post-Kt in the tumor area and (b) pre-Ve in the surrounding area of ​​the tumor.


    Figure 2 Event-free survival curves of subgroups stratified according to the median value of (a) post-Kt in the tumor area and (b) pre-Ve in the surrounding area of ​​the tumor.


    Figure 3 Stratification according to the median value of (a)post-Kt, (b)pre-Ve in the tumor area and (c)pre-Ve, (d)post-Ve, (e)post-ADC in the surrounding area of ​​the tumor Survival curve of the subgroup.


    Figure 3 Stratification according to the median value of (a)post-Kt, (b)pre-Ve in the tumor area and (c)pre-Ve, (d)post-Ve, (e)post-ADC in the surrounding area of ​​the tumor Survival curve of the subgroup.


    The DWI and DCE-MRI parameters of the tumor and peritumoral area can reflect the chemotherapy response and predict EFS and overall survival rate.


    Original source: Original source:

    Yuewen Hao,Rui An,Yingsen Xue,et al.


    Yuewen Hao,Rui An,Yingsen Xue,et al.
    Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response.
    DOI: org/10.
    1007/s00330-020-07338-y">10.
    1007/s00330-020-07338-y Yuewen Hao,Rui An,Yingsen Xue,et value of tumoral and peritumoral al.
    Prognostic Magnetic Resonance Parameters in osteosarcoma patients Chemotherapy for Response Monitoring the DOI:.
    org/10.
    1007/s00330-020-07338-y">10.
    1007 / Y-s00330-020-07338org/10.
    1007/s00330-020-07338-y"> 10.
    1007 / s00330-020-07338-Y in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.